ES2660822T3 - Inhibidores de beta-hidrolasa para tratamiento del cáncer - Google Patents

Inhibidores de beta-hidrolasa para tratamiento del cáncer Download PDF

Info

Publication number
ES2660822T3
ES2660822T3 ES13838498.7T ES13838498T ES2660822T3 ES 2660822 T3 ES2660822 T3 ES 2660822T3 ES 13838498 T ES13838498 T ES 13838498T ES 2660822 T3 ES2660822 T3 ES 2660822T3
Authority
ES
Spain
Prior art keywords
amino
furanone
oxy
methyl
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13838498.7T
Other languages
English (en)
Spanish (es)
Inventor
Jack R. Wands
Suzanne DE LAMONTE
Arihiro AIHARA
Mark Jon OLSEN
John-Michael THOMAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhode Island Hospital
Midwestern University Downers Grove
Midwestern University Glendale
Original Assignee
Rhode Island Hospital
Midwestern University Downers Grove
Midwestern University Glendale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital, Midwestern University Downers Grove, Midwestern University Glendale filed Critical Rhode Island Hospital
Application granted granted Critical
Publication of ES2660822T3 publication Critical patent/ES2660822T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES13838498.7T 2012-09-21 2013-09-20 Inhibidores de beta-hidrolasa para tratamiento del cáncer Active ES2660822T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261704014P 2012-09-21 2012-09-21
US201261704014P 2012-09-21
PCT/US2013/061050 WO2014047519A2 (en) 2012-09-21 2013-09-20 Inhibitors of beta-hydrolase for treatment of cancer

Publications (1)

Publication Number Publication Date
ES2660822T3 true ES2660822T3 (es) 2018-03-26

Family

ID=50342080

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13838498.7T Active ES2660822T3 (es) 2012-09-21 2013-09-20 Inhibidores de beta-hidrolasa para tratamiento del cáncer
ES17202827T Active ES2865412T3 (es) 2012-09-21 2013-09-20 Inhibidores de beta-hidrolasa para tratamiento del cáncer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17202827T Active ES2865412T3 (es) 2012-09-21 2013-09-20 Inhibidores de beta-hidrolasa para tratamiento del cáncer

Country Status (10)

Country Link
US (8) US9771356B2 (https=)
EP (2) EP3345596B1 (https=)
JP (1) JP6469009B2 (https=)
KR (1) KR102137180B1 (https=)
CN (2) CN104902889A (https=)
AU (1) AU2013317791B2 (https=)
CA (1) CA2885762C (https=)
ES (2) ES2660822T3 (https=)
HK (1) HK1208805A1 (https=)
WO (2) WO2014047519A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660822T3 (es) 2012-09-21 2018-03-26 Rhode Island Hospital Inhibidores de beta-hidrolasa para tratamiento del cáncer
EP3652542A1 (en) * 2017-07-14 2020-05-20 Protea Biopharma N.V. Methods and means for diagnosing and/or treating a fatiguing illness
WO2019246093A1 (en) * 2018-06-18 2019-12-26 Midwestern University Monoclonal antibodies targeting epitopes of asph
CN109364251A (zh) * 2018-12-06 2019-02-22 苏州大学 Tet蛋白在治疗抑郁症中的应用
CA3130396A1 (en) 2019-02-15 2020-08-20 Midwestern University Isotopically-stabilized tetronimide compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD39717A (https=)
DE39717C (de) H. LEHMANN in München, Enhuberstr. 5 part Bleistifthalter
EP0232258B1 (en) 1985-08-02 1990-05-02 Chevron Research And Technology Company Herbicidal 2-(oxa or thia heterocycle)5-amino-3-oxo-4-(substituted-phenyl)-2,3-dihydrofurans
US5314913A (en) * 1992-12-08 1994-05-24 American Home Products Corporation 4- or 5-(substituted sulfonyl)methyl-3(2H)-furanones
JPH09110853A (ja) * 1995-10-12 1997-04-28 Kikkoman Corp 4‐アシルオキシフラノン誘導体又はその塩及びその製造方法
US5698585A (en) 1995-04-13 1997-12-16 Kikkoman Corporation Pharmaceutical preparation for prevention and/or treatment for cataract
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2283100A1 (en) 1997-03-14 1998-09-24 Merck Frosst Canada & Co. (methylsulfonyl)phenyl-2-(5h)-furanones with oxygen link as cox-2 inhibitors
US20030031670A1 (en) 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US6835370B2 (en) 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20050123545A1 (en) 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
WO2003018575A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase
US6667330B2 (en) * 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
AU2002950862A0 (en) 2002-08-19 2002-09-12 Biosignal Pty Ltd Furanone derivatives and methods of making same
WO2004035812A2 (en) 2002-10-16 2004-04-29 Isis Innovation Limited Asparaginyl hydroxylases and modulators thereof
US7642361B2 (en) * 2004-01-09 2010-01-05 Eli Lilly And Company Thiophene and furan compounds
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ido阻害剤
MX2012014273A (es) * 2010-06-07 2013-03-22 Novomedix Llc Compuestos furanilo y su uso.
ES2660822T3 (es) 2012-09-21 2018-03-26 Rhode Island Hospital Inhibidores de beta-hidrolasa para tratamiento del cáncer

Also Published As

Publication number Publication date
US20150210677A1 (en) 2015-07-30
WO2014047447A2 (en) 2014-03-27
WO2014047519A3 (en) 2014-05-30
US9771356B2 (en) 2017-09-26
AU2013317791B2 (en) 2018-05-10
EP2897607A2 (en) 2015-07-29
US20190300519A1 (en) 2019-10-03
EP2897607A4 (en) 2016-10-05
US20180009798A1 (en) 2018-01-11
JP6469009B2 (ja) 2019-02-13
CN110818660B (zh) 2023-09-12
KR102137180B1 (ko) 2020-07-24
HK1208805A1 (zh) 2016-03-18
US10787445B2 (en) 2020-09-29
EP3345596B1 (en) 2021-01-20
WO2014047447A3 (en) 2015-07-30
CA2885762A1 (en) 2014-03-27
WO2014047519A2 (en) 2014-03-27
US20220251076A1 (en) 2022-08-11
US20190002453A1 (en) 2019-01-03
AU2013317791A1 (en) 2015-05-07
US20200361925A1 (en) 2020-11-19
CN104902889A (zh) 2015-09-09
ES2865412T3 (es) 2021-10-15
CA2885762C (en) 2022-05-03
CN110818660A (zh) 2020-02-21
KR20150079616A (ko) 2015-07-08
US10106532B2 (en) 2018-10-23
EP3345596A2 (en) 2018-07-11
US10351555B2 (en) 2019-07-16
US10710995B2 (en) 2020-07-14
EP2897607B1 (en) 2017-11-22
US20180237427A1 (en) 2018-08-23
US20210032233A1 (en) 2021-02-04
JP2015531351A (ja) 2015-11-02
EP3345596A3 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
ES2620634T3 (es) Activadores de piruvato quinasa humana
CN102424681B (zh) 酰基四氢-β-咔啉类化合物及其衍生物、用途及其制备方法
ES2660822T3 (es) Inhibidores de beta-hidrolasa para tratamiento del cáncer
CN101959404A (zh) 单磷酸腺苷活化蛋白激酶调节剂
CN102015606A (zh) IRE-1α抑制剂
CN107531683B (zh) Usp7抑制剂化合物及使用方法
US20240051936A1 (en) Isoindolinone compounds
ES2389678T3 (es) Un inhibidor de la quinasa C-Kit para su uso en el tratamiento de tumores del estroma gastrointestinal o mastocitosis
BR112016018371B1 (pt) Derivados de indolona substituídos com pirrol, composição os compreendendo e uso dos mesmos
ES2911183T3 (es) Compuesto para inhibir selectivamente quinasas y uso del mismo
JP4564713B2 (ja) 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
JPWO2003007931A1 (ja) スルホンアミド誘導体
ES2923652T3 (es) Inhibidores de la actividad LDHA
WO2019120237A1 (zh) 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途
CN106831747A (zh) 五元杂环取代的n-烷基酰胺类wnt通路抑制剂
JP2005526054A (ja) 化合物
ES2367587T3 (es) Derivados de tiadiazolina para el tratamiento del cancer.
KR20060033671A (ko) 신규한([1,3]티아졸로[5,4-b]피리딘-2-일)-2-아지리딘카르복사마이드 유도체